Endobios is developing the ENB-00X asset, an early preclinical drug candidate to treat epilepsy and neuropathic pain.

Endobios is developing the ENB-00X asset, an early preclinical drug candidate to treat epilepsy and neuropathic pain.

The ENB-00x are novel natural small cyclic peptides, isolated from a marine-derived microbe, which demonstrated promising in vivo anticonvulsant activity, as assessed externally by the Epilepsy Therapy Screening Program (ETSP, NIH, USA). A secondary capability against neuropathic pain was also suggested as plausible by the ETSP. These datasets lay the foundational groundwork of the ENB-00x platform, a candidate scaffold for anticonvulsant therapy in the early stages of preclinical development. The ENB-00x value propositions include pivoting options, off-label potential and are synthesizable. A patent was submitted, with only minor (correctable) notes from the patent reviewer. Although the mechanism of action is currently inconclusive, ENB-00x has demonstrated both in vivo and in vitro safety, with no toxicity observed when all compounds were tested against five distinct cell lines, including SF268 (CNS) and HepG2 (liver), at 50 µM doses. Currently, Endobios owns 100% of the IP rights.